SG11201807912SA - Vaccine against rsv - Google Patents
Vaccine against rsvInfo
- Publication number
- SG11201807912SA SG11201807912SA SG11201807912SA SG11201807912SA SG11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- archimedesweg
- leiden
- rsv
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16163807 | 2016-04-05 | ||
PCT/EP2017/057957 WO2017174564A1 (fr) | 2016-04-05 | 2017-04-04 | Vaccin contre le rsv |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807912SA true SG11201807912SA (en) | 2018-10-30 |
Family
ID=55661317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807912SA SG11201807912SA (en) | 2016-04-05 | 2017-04-04 | Vaccine against rsv |
Country Status (18)
Country | Link |
---|---|
US (3) | US10729757B2 (fr) |
EP (1) | EP3439694A1 (fr) |
JP (2) | JP7233928B2 (fr) |
KR (3) | KR102491447B1 (fr) |
CN (1) | CN109069612A (fr) |
AU (1) | AU2017248018A1 (fr) |
BR (1) | BR112018070323A2 (fr) |
CA (1) | CA3018139A1 (fr) |
CL (1) | CL2018002825A1 (fr) |
EA (1) | EA201892250A1 (fr) |
IL (1) | IL262109B2 (fr) |
MA (1) | MA43762A (fr) |
MX (1) | MX2018012095A (fr) |
MY (1) | MY193584A (fr) |
PE (1) | PE20190433A1 (fr) |
PH (1) | PH12018501912A1 (fr) |
SG (1) | SG11201807912SA (fr) |
WO (1) | WO2017174564A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2988780T1 (sl) | 2013-04-25 | 2019-05-31 | Janssen Vaccines & Prevention B.V. | Stabilizirani topni prefuzijski RSV F polipeptidi |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
DK3319633T3 (da) | 2015-07-07 | 2021-02-01 | Janssen Vaccines & Prevention Bv | Vaccine mod rsv |
EP4011451A1 (fr) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Vaccins contre le virus respiratoire |
CA3018941A1 (fr) * | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Proteines f du vrs de pre-fusion solubles stabilisees |
KR102491447B1 (ko) | 2016-04-05 | 2023-01-20 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
EP3464331B1 (fr) | 2016-05-30 | 2020-10-28 | Janssen Vaccines & Prevention B.V. | Protéines f vrs pre-fusion stabilisée |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
SG11202001458SA (en) * | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
EP3969045A1 (fr) | 2019-05-15 | 2022-03-23 | Janssen Vaccines & Prevention B.V. | Traitement prophylactique d'une infection par le virus respiratoire syncytial avec un vaccin à base d'adénovirus |
KR20220008875A (ko) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여 |
IL299515A (en) | 2020-06-29 | 2023-02-01 | Janssen Vaccines & Prevention Bv | Immune combination against respiratory syncytial virus infection |
CN112220921B (zh) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | 一种针对呼吸道合胞病毒感染的组合疫苗 |
WO2022175479A1 (fr) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial |
CN114277039A (zh) * | 2021-10-25 | 2022-04-05 | 浙江君怡生物科技有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
WO2023198815A1 (fr) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Administration séquentielle d'adénovirus |
WO2024041773A1 (fr) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Protéines rsv-f |
WO2024069420A2 (fr) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Compositions immunogènes comprenant un trimère de protéine f rsv |
WO2024089634A1 (fr) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Compositions immunogènes contre la grippe et le vrs |
WO2024089633A1 (fr) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Molécules d'arn codant pour le vrs-f et vaccins les contenant |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (fr) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Composés recombinants d'ADN et l'expression de polypeptides comme le tPA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
WO1995034671A1 (fr) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Systemes de vecteurs adenoviraux et lignees cellulaires complementaires |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
ATE445705T1 (de) | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante adenoviren zur gentherapie |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
CZ438398A3 (cs) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998010087A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Vecteurs d'adenovirus de chimpanze |
EP1760151B1 (fr) | 1996-11-20 | 2012-03-21 | Crucell Holland B.V. | Compositions d'adenovirus pouvant être obtenues au moyen d'un procédé de production et purification amélioré |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
CA2283253A1 (fr) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Lignees cellulaires de complementation de la region e1 d'un adenovirus |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
KR100912362B1 (ko) | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
ES2323991T3 (es) | 1998-11-16 | 2009-07-28 | Introgen Therapeutics, Inc. | Formulacion de adenovirus para terapia genica. |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
DE60043126D1 (de) | 1999-05-17 | 2009-11-19 | Crucell Holland Bv | Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
AU4346101A (en) | 2000-03-07 | 2001-09-17 | Merck & Co., Inc. | Adenovirus formulations |
AU2001259625A1 (en) | 2000-05-08 | 2001-11-20 | Davisco Foods International, Inc. | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
JP4550421B2 (ja) | 2001-12-12 | 2010-09-22 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | ウイルスの保存のための組成物 |
BR0306925A (pt) | 2002-01-18 | 2004-11-09 | Schering Ag | Formulações estabilizadas de adenovìrus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
IL164802A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
IL164803A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Means and methods for the production of adenovirusvectors |
ATE360683T1 (de) | 2002-05-14 | 2007-05-15 | Merck & Co Inc | Verfahren zur reinigung von adenovirus |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
EP1585964A4 (fr) | 2002-08-28 | 2008-07-16 | Introgen Therapeutics Inc | Procedes chromatographiques de purification d'adenovirus |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CN102719478A (zh) | 2004-01-23 | 2012-10-10 | P.安杰莱蒂分子生物学研究所 | 黑猩猩腺病毒疫苗载运体 |
CA2555412C (fr) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Procedes de purification de virus |
US8574595B2 (en) | 2005-04-11 | 2013-11-05 | Crucell Holland B.V. | Virus purification using ultrafiltration |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
WO2008133663A2 (fr) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Compositions immunogènes à codons modifiés et procédés d'utilisation |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
SI2222710T1 (sl) | 2007-12-24 | 2016-11-30 | Id Biomedical Corporation Of Quebec | Rekombinatni RSV antigeni |
ATE545028T1 (de) | 2008-02-29 | 2012-02-15 | Tibotec Pharm Ltd | Verfahren zur identifizierung von inhibitoren gegen viren, die ein klasse-i-fusionsprotein verwenden |
WO2010060719A1 (fr) | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Procédé pour la production de vecteurs adénoviraux |
MX2011006205A (es) * | 2008-12-09 | 2011-09-01 | Novavax Inc | Proteinas f del vrs modificadas y metodos de uso de las mismas. |
EP3385387B1 (fr) | 2009-02-02 | 2021-08-25 | GlaxoSmithKline Biologicals SA | Séquences d'acide aminé et d'acide nucléique d'adénovirus simien, vecteurs les contenant, et utilisations afférentes |
CA2766205A1 (fr) | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccin renfermant au moins deux antigenes de la proteine f du paramyxovirus |
SG176829A1 (en) | 2009-06-24 | 2012-01-30 | Glaxosmithkline Biolog Sa | Recombinant rsv antigens |
HUE058971T2 (hu) | 2009-07-15 | 2022-09-28 | Glaxosmithkline Biologicals Sa | RSV F fehérjekészítmények és eljárások azok elõállítására |
WO2011020079A1 (fr) | 2009-08-13 | 2011-02-17 | Calmune Corporation | Anticorps contre le virus respiratoire syncytial (vrs) humain et procédés d'utilisation |
DK2488635T3 (en) | 2009-10-15 | 2014-02-24 | Crucell Holland Bv | A method for purifying adenovirus of cultures with high cell density |
BR112012008516B1 (pt) | 2009-10-15 | 2021-10-19 | Janssen Vaccines & Prevention B.V. | Método para purificar partículas de adenovírus a partir de uma suspensão de célula |
WO2011050168A2 (fr) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Immunogènes du rsv, anticorps dirigés contre le rsv et compositions associées |
AU2011214262B2 (en) | 2010-02-15 | 2015-05-21 | Crucell Holland B.V. | Method for the production of Ad26 adenoviral vectors |
BR112012031638B1 (pt) | 2010-07-09 | 2021-01-12 | Janssen Vaccines & Prevention B.V. | anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado |
ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
JP5770952B2 (ja) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
MY169352A (en) * | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
WO2014005643A1 (fr) | 2012-07-05 | 2014-01-09 | Okairos Ag | Nouveaux régimes de primo-vaccination-rappel impliquant des polypeptides immunogènes codés par des polynucléotides |
JP6210998B2 (ja) * | 2012-11-15 | 2017-10-11 | 一般財団法人化学及血清療法研究所 | ベクターワクチンおよび生ワクチンの併用による感染症の予防方法 |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
CN112851766A (zh) | 2013-03-13 | 2021-05-28 | 美国政府(由卫生和人类服务部的部长所代表) | 融合前rsv f蛋白和其用途 |
EP3567051A1 (fr) | 2013-04-15 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Anticorps humains se liant à la protéine rsv g |
CN105164155B (zh) | 2013-04-15 | 2020-01-03 | 扬森疫苗与预防公司 | 结合到rsv g蛋白的人类抗体 |
SI2988780T1 (sl) | 2013-04-25 | 2019-05-31 | Janssen Vaccines & Prevention B.V. | Stabilizirani topni prefuzijski RSV F polipeptidi |
MY171210A (en) * | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
CA2919353C (fr) | 2013-07-25 | 2022-08-23 | Avatar Medical, Llc | Proteines f de pre-fusion rsv a stabilisation conformationnelle |
PE20160527A1 (es) | 2013-09-19 | 2016-05-20 | Crucell Holland Bv | Formulaciones de adenovirus mejoradas |
MX2016016533A (es) | 2014-06-13 | 2017-05-01 | Glaxosmithkline Biologicals Sa | Combinaciones inmunogenas. |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
DK3319633T3 (da) | 2015-07-07 | 2021-02-01 | Janssen Vaccines & Prevention Bv | Vaccine mod rsv |
CA3018941A1 (fr) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Proteines f du vrs de pre-fusion solubles stabilisees |
KR102491447B1 (ko) | 2016-04-05 | 2023-01-20 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
EP3464331B1 (fr) | 2016-05-30 | 2020-10-28 | Janssen Vaccines & Prevention B.V. | Protéines f vrs pre-fusion stabilisée |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
SG11202104522UA (en) | 2018-11-13 | 2021-05-28 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
CA3137448A1 (fr) | 2019-04-25 | 2020-10-29 | Janssen Vaccines & Prevention B.V. | Antigenes recombines de la grippe |
EP3969045A1 (fr) | 2019-05-15 | 2022-03-23 | Janssen Vaccines & Prevention B.V. | Traitement prophylactique d'une infection par le virus respiratoire syncytial avec un vaccin à base d'adénovirus |
WO2021198413A1 (fr) | 2020-04-02 | 2021-10-07 | Janssen Vaccines & Prevention B.V. | Compositions de vaccin stabilisées |
IL299515A (en) | 2020-06-29 | 2023-02-01 | Janssen Vaccines & Prevention Bv | Immune combination against respiratory syncytial virus infection |
-
2017
- 2017-04-04 KR KR1020227002657A patent/KR102491447B1/ko active IP Right Grant
- 2017-04-04 KR KR1020187031414A patent/KR102401247B1/ko active IP Right Grant
- 2017-04-04 CA CA3018139A patent/CA3018139A1/fr active Pending
- 2017-04-04 MY MYPI2018703646A patent/MY193584A/en unknown
- 2017-04-04 EP EP17715691.6A patent/EP3439694A1/fr active Pending
- 2017-04-04 MA MA043762A patent/MA43762A/fr unknown
- 2017-04-04 KR KR1020227016835A patent/KR102500970B1/ko active IP Right Grant
- 2017-04-04 US US16/091,257 patent/US10729757B2/en active Active
- 2017-04-04 AU AU2017248018A patent/AU2017248018A1/en active Pending
- 2017-04-04 PE PE2018001916A patent/PE20190433A1/es unknown
- 2017-04-04 CN CN201780021794.1A patent/CN109069612A/zh active Pending
- 2017-04-04 WO PCT/EP2017/057957 patent/WO2017174564A1/fr active Application Filing
- 2017-04-04 EA EA201892250A patent/EA201892250A1/ru unknown
- 2017-04-04 IL IL262109A patent/IL262109B2/en unknown
- 2017-04-04 SG SG11201807912SA patent/SG11201807912SA/en unknown
- 2017-04-04 JP JP2018551163A patent/JP7233928B2/ja active Active
- 2017-04-04 MX MX2018012095A patent/MX2018012095A/es unknown
- 2017-04-04 BR BR112018070323A patent/BR112018070323A2/pt unknown
-
2018
- 2018-09-07 PH PH12018501912A patent/PH12018501912A1/en unknown
- 2018-10-04 CL CL2018002825A patent/CL2018002825A1/es unknown
-
2020
- 2020-06-24 US US16/946,485 patent/US11338031B2/en active Active
-
2022
- 2022-05-20 US US17/664,290 patent/US11801297B2/en active Active
- 2022-11-24 JP JP2022187453A patent/JP2023029889A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019510497A (ja) | 2019-04-18 |
CL2018002825A1 (es) | 2018-11-16 |
WO2017174564A1 (fr) | 2017-10-12 |
KR20180132761A (ko) | 2018-12-12 |
US11338031B2 (en) | 2022-05-24 |
JP2023029889A (ja) | 2023-03-07 |
BR112018070323A2 (pt) | 2019-01-29 |
KR20220018618A (ko) | 2022-02-15 |
EA201892250A1 (ru) | 2019-03-29 |
IL262109B (en) | 2022-12-01 |
KR102401247B1 (ko) | 2022-05-25 |
US20190125854A1 (en) | 2019-05-02 |
US10729757B2 (en) | 2020-08-04 |
KR102491447B1 (ko) | 2023-01-20 |
PH12018501912A1 (en) | 2019-06-17 |
AU2017248018A1 (en) | 2018-09-27 |
IL262109B2 (en) | 2023-04-01 |
PE20190433A1 (es) | 2019-03-21 |
MX2018012095A (es) | 2019-01-10 |
KR20220075436A (ko) | 2022-06-08 |
US11801297B2 (en) | 2023-10-31 |
IL262109A (en) | 2018-11-29 |
US20220288186A1 (en) | 2022-09-15 |
MY193584A (en) | 2022-10-19 |
CA3018139A1 (fr) | 2017-10-12 |
KR102500970B1 (ko) | 2023-02-17 |
US20200360506A1 (en) | 2020-11-19 |
JP7233928B2 (ja) | 2023-03-07 |
MA43762A (fr) | 2021-04-21 |
EP3439694A1 (fr) | 2019-02-13 |
CN109069612A (zh) | 2018-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807912SA (en) | Vaccine against rsv | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201901351UA (en) | A patient interface, system and method | |
SG11201902531QA (en) | Liquid pharmaceutical composition | |
SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |